🧾 What This Document Is

This is an SEC filing called a Schedule 14D-9. Think of it as a formal "Q&A and Announcement" document a company must file when someone is trying to buy it through a tender offer. It’s not the offer itself, but Apellis' official response and collection of related communications about the deal. In this case, it’s about Biogen's planned acquisition of Apellis.

🏢 What The Company Does

👉 In simple terms, Apellis Pharmaceuticals is a biotech company focused on developing treatments for serious diseases by targeting the complement system, a part of the immune system. They are the company being acquired. Biogen, the acquirer, is a much larger, well-known biotech giant famous for its neurological drugs (like those for multiple sclerosis and Alzheimer's). This deal is a major strategic move for Biogen to expand its drug portfolio.

💰 The Deal’s Financial Highlights

The core of this document is the planned acquisition. Here are the key financial terms from the merger agreement:

• Offer Price: Biogen will start a tender offer to buy all of Apellis' outstanding common stock.
• Price Per Share: While the exact number isn't in this filing, the attached press release (Exhibit 99.1) would contain it. The filing confirms the deal is structured as an all-cash transaction.
• Total Value: The offer would value Apellis at a significant premium to its recent trading price, which is typical in such acquisitions. (The precise market cap would be calculated from the offer price per share and the number of shares outstanding).

🚀 Key Moves & Actions

Several critical actions are outlined:

• The Merger Agreement: Apellis, Biogen, and a Biogen subsidiary signed a definitive merger agreement on March 31, 2026.
• The Two-Step Process: First comes the tender offer, where Biogen directly asks shareholders to sell their shares. If successful, a short "back-end" merger will follow, allowing Biogen to squeeze out any remaining shareholders and fully own Apellis.
• Board Recommendation: The Apellis Board of Directors has recommended that shareholders tender their shares in the offer. This "endorsement" is the most important signal in the filing.

📦 What This Means for Apellis' Future

• Loss of Independence: If completed, Apellis would stop being a publicly traded company and become a wholly owned subsidiary of Biogen. Its stock would be delisted.
• Strategic Fit: For Biogen, this acquisition adds Apellis' approved drug Empaveli (for a rare blood disorder) and its promising pipeline, including treatments for geographic atrophy (an advanced form of macular degeneration), to its own portfolio.

🔮 What's Next: The Process

The filing lays out the upcoming steps:

1. Launch of the Tender Offer: Biogen will formally start the offer, which must remain open for at least 20 business days.
2. Stockholder Decision: Apellis shareholders must decide whether to tender their shares at the offer price.
3. Regulatory Approval: The deal requires approval from relevant government regulators (likely the FTC).
4. Merger Completion: If all conditions are met, the acquisition will close, and Apellis shareholders will get cash for their shares.

⚖️ The Big Picture

👍 Strengths / Why This Might Be Good:

• Provides a clear, immediate cash exit for shareholders at a premium price.
• Apellis' science and products get the backing and resources of a large, established company like Biogen.
• The Board of Directors has reviewed the deal and is recommending it.

⚠️ Risks / What Could Go Wrong:

• Regulatory Hurdles: Antitrust regulators could block or demand concessions.
• Deal Breakup: If conditions aren't met, the deal could fall apart, likely causing Apellis' stock price to drop significantly.
• No Future Upside: Shareholders give up any potential future growth of Apellis as an independent company.

🧠 The Analogy

Think of this like a popular, innovative local restaurant (Apellis) being bought out by a massive national restaurant chain (Biogen). The local owners and investors get a big, guaranteed payout now, but the restaurant might change its menu or brand over time. The local investors lose their chance to see if the restaurant could have become a national chain on its own.

📇 Key Contacts & People

For Apellis Pharmaceuticals, Inc.:

• Name: Cedric Francois, M.D., Ph.D.
• Title: President and Chief Executive Officer
• Address: 100 Fifth Avenue, Waltham, MA 02451
• Phone: (617) 977-5700

Legal Advisors:

• Apellis' Counsel: Wilmer Cutler Pickering Hale and Dorr LLP
  • Contacts: Stuart M. Falber, Hal J. Leibowitz, Andrew R. Bonnes
  • Address: 60 State Street, Boston, Massachusetts 02109
  • Phone: (617) 526-6000
• Biogen's Counsel (likely): Wachtell, Lipton, Rosen & Katz
  • Contacts: Adam O. Emmerich, Esq., Ronald C. Chen, Esq., Victor Goldfeld, Esq.
  • Address: 51 West 52nd Street, New York, New York 10019
  • Phone: (212) 403-1000

🧩 Final Takeaway

This filing is Apellis' formal notification to the market that its Board supports and recommends Biogen's acquisition offer. The key takeaway is the Board's endorsement, which signals confidence in the deal's value and sets the stage for shareholders to make their own decision when the tender offer officially begins.